TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients fulfilling ACS criteria with or without known diabetes.~Exclusion Criteria:~* Patients under 18 years old.~* Killip II class or SaO2 ≤ 90%.~* Blood creatinine ≥ 180 µmol/L~* Potassium serum ≥ 6.5 mmol/L.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- glucose insulin potassium (GIK) (Type: PLACEBO_COMPARATOR): Glucose + insulin +6 potassium (GIK) infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours.
- GIK and intensive insulin therapy (Type: EXPERIMENTAL): GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
- Control group (Type: NO_INTERVENTION): No intervention and patients were treated with updated international recommendations of acute coronary syndrome.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with a diagnosis of first AIS due to distal \[M2 segment and beyond\] occlusion or perforator occlusion~* Perfusion abnormalities observed on Computed Tomography Perfusion (CTP)~* Mild to moderate stroke severity~* Pre-stroke mRS \<4~* Written informed consent obtained from patient and/or medical treatment decision maker prior to study-start (upon admission).~Exclusion Criteria:~* Administration of intravenous thrombolytic therapy in distal occlusion as etiology of AIS~* Intervention by endovascular thrombectomy (EVT)~* Known allergy or anaphylaxis to adrenocorticotropic hormone (ACTH) or melanocortins or any of the excipients listed in the Investigator's Brochure~* Any evidence of hepatic (defined as three times standard range) or renal impairment (defined as estimated glomerular filtration rate (eGFR) \<50 mL/min/1.73 m²)~* Any other medical condition which may interfere with the study protocol~* Female who is pregnant (confirmed by positive serum beta human chorionic gonadotropin (β-HCG) pregnancy test prior to baseline) or lactating~* Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device) or a lifestyle excluding pregnancy~* Unable to undergo MRI brain evaluation~* Not suitable for trial participation according to judgment of the Principal Investigator (PI)~* Patients starting afamelanotide 24 hours or more from ictus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Afamelanotide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral Febuxostat in Participants With Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has one or more of the American Rheumatism Association criteria for the diagnosis of gout.~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~* Must have a serum urate level greater than or equal to 8.0 milligram per deciliter (mg/dL).~Exclusion Criteria:~* Have a severe, unstable, or life threatening medical condition that would likely prevent them from completing this study.~* Has a known body reaction to febuxostat, allopurinol, naproxen, any other non-steroidal anti-inflammatory drug (NSAID), aspirin, lansoprazole, colchicine, or any components in their formulation.~* History of xanthinuria.~* Alcohol consumption greater than 14/week.~* History of significant concomitant illness.~* Active liver or peptic ulcer disease.~* Has rheumatoid arthritis requiring treatment.~* Has estimated creatinine clearance less than 30 milliliter per minute (mL/min) calculated using the Cockcroft-Gault formula corrected for ideal body weight.~* Requires therapy with any other urate-lowering drug other than the study drug; long-term use of NSAIDs and COX-2 inhibitors; salicylates; thiazide diuretics; losartan; azathioprine; mercaptopurine; theophylline; intravenous (IV) colchicine; cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole;trimethoprim.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Febuxostat 40 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 80 mg QD (Type: EXPERIMENTAL): None
- Allopurinol 200 mg or 300 mg QD (Type: ACTIVE_COMPARATOR): (dependent on renal function)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female child outpatients aged 5 to 18 years~2. Diagnosis of PWS confirmed by genetic testing and patient medical records and history~3. Stable pharmacologic, educational, behavioral and/or dietary interventions for 4 weeks prior to the study start, and for the duration of the study.~4. Have a physical exam and laboratory results that are within the norms for PWS~5. Have a parent/caregiver/guardian that is able to consent for their participation and complete assessments regarding the child's development and behavior improvement throughout the study.~Exclusion Criteria:~1. Exposure to any investigational agent in the 30 days prior to randomization~2. Prior chronic treatment with oxytocin.~3. A primary psychiatric diagnosis other than ASD, including bipolar disorder, psychosis, schizophrenia, PTSD or major depressive disorder. These patients will be excluded due to potential confounding results.~4. Pregnant or lactating patients. IN-OXT has not been studied in pregnant or lactating women.~5. A medical condition that might interfere with the conduct of the study, confound interpretation of study results or endanger their own well-being.~6. Plan to initiate or change nonpharmacologic or pharmacologic interventions during the course of the study.~7. Females using an estrogen-based contraceptive. As an alternative to an estrogen based contraceptive, subjects will be counseled to use progesterone-based contraceptives; cervical caps; cervical sponges; or spermicidal foam in combination with a condom. Subjects will need to use a double barrier method to be in the study.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal Oxytocin (Type: EXPERIMENTAL): Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
- Matched Placebo (Type: PLACEBO_COMPARATOR): Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ASA 1\~2, 2. age of 40- 80 years~Exclusion Criteria:~1. patients who cannot read,~2. patients refusing the study~3. allergy to magnesium~4. chronic pain~5. chronic abuse of opioid or NSAID~6. neuromuscular block~7. atrioventricular conductance block~8. liver failure,

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- normal saline (Type: EXPERIMENTAL): None
- magnesium sulfate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically and clinically confirmed multiple myeloma~  * Relapsed and/or refractory after chemotherapy or transplantation~    * Patients with prior allogeneic transplantation must not have evidence of active graft-vs-host disease requiring immune suppression~* Measurable disease defined by quantitative immune globulin levels in serum and/or urine and bone marrow plasmacytosis~  * Patients with nonsecretory disease are eligible provided at least 1 plasmacytoma lesion is accurately measurable by MRI or CT scan~* No known CNS involvement~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2 OR~* Karnofsky 60-100%~Life expectancy~* More than 3 months~Hematopoietic~* See Disease Characteristics~* Absolute neutrophil count at least 1,000/mm\^3\*~* Platelet count at least 50,000/mm\^3\* NOTE: \*Unless secondary to bone marrow plasmacytosis (more than 80% involvement)~Hepatic~* Bilirubin less than 2 times normal~* AST/ALT no greater than 3 times upper limit of normal~Renal~* Creatinine no greater than 2 mg/dL~Cardiovascular~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~Other~* Seizures allowed if under adequate control~* No severe skin reactions from prior thalidomide~* No prior allergic reactions attributed to agents used in this study~* No sensory or motor neuropathy grade II or greater~* No other uncontrolled concurrent illness that would preclude study therapy~* No ongoing or active infection~* No psychiatric illness or social situations that would preclude study compliance~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 2 effective methods of contraception for 1 month before, during, and for 1 month after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~* See Chemotherapy~* At least 6 weeks since prior thalidomide~Chemotherapy~* See Disease Characteristics~* No more than 4 prior chemotherapy regimens, including autologous and/or allogeneic stem cell transplantation regimens~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered~Endocrine therapy~* Concurrent continuous steroids allowed for chronic treatment of disorders other than myeloma~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No prior oblimersen~* No other concurrent anticancer therapies or investigational agents~* No concurrent combination antiretroviral therapy for HIV-positive patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be considered eligible for enrolment into the study, subjects must;~1. Be able to give written informed consent,~2. Be between 18 and 75 years of age,~3. Be in generally good health as determined by the investigator OR have mild gastrointestinal discomfort, such as mild indigestion,~4. Have a positive urease breath test (\> 1.5)~Exclusion Criteria:~Subjects will be excluded from the study if they meet any of the below criteria;~1. Are less than 18 and greater than 75 years of age,~2. Females are pregnant, lactating or wish to become pregnant during the study.~3. Are hypersensitive to any of the components of the test product,~4. Have a significant acute or chronic, unstable and untreated disease or any condition which contraindicates, in the investigators judgement, entry to the study,~5. Have an active gastrointestinal disorder or previous gastrointestinal surgery,~6. Having a condition or have taken a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; to include proton pump inhibitors or gastroprotective medicines,~7. Have taking antibiotics in the past 3 months,~8. Prior eradication therapy with antibiotics for H. pylori infection,~9. Have not made any major dietary changes in the past 3 months,~10. Are taking non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks of baseline visit or for the duration of the trial,~11. History of illicit drug use,~12. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial,~13. Subjects may not be receiving treatment involving experimental drugs,~14. If the subject has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study,~15. Have a malignant disease or any concomitant end-stage organ disease,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo - 2 doses per day for 4 weeks
- Pylopass (Type: ACTIVE_COMPARATOR): Probiotic - 2 doses per day for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis (clinical and histological features) of Hailey Hailey or Darier diseases.~* Moderate to very severe lesions located in large folds~* Patient aged 18 ans or more~* Patient with health coverage~* Patient who have signed the consent form~* Patient proficient into filling out the questionnaires.~Exclusion Criteria:~* Hypersensibility to toxin or excipients~* Myastheny~* Deglutition's problems~* Past medical history of dysphagia or aspiration pneumonia~* Pregnancy (positive B-HCG test performed a maxima 72h before) or breastfeeding~* Mental , physical incapacity to fill in the questionnaires~* Guardianship patients~* Skin infections at the inclusion visit~* Application in the last 7 days at the site of injection of local treatments (apart emollients or antiseptics) or injections of botulism toxin or dynamic phototherapy or laser in the last 6 months.~* Systemic treatment with aminosides in the last 15 days~* Inclusion in another study in the last 2 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Botulism Toxin treatment (Type: EXPERIMENTAL): Injection of 50 UI Botulism toxin for the treated zone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has paroxysmal, persistent or permanent non-valvular atrial fibrillation (AF)~* Eligible for long term warfarin~* CHADS score \>= 1 \[congestive heart failure (CHF), history of high blood pressure, 75 years of age or older, diabetes, prior stroke or transient ischemic attack (TIA)\]~Exclusion Criteria:~* Contraindicated for warfarin~* Contraindicated for aspirin or clopidogrel (Plavix)~* Congestive heart failure (CHF) Class 4~* Implanted mechanical valve~* Atrial septal or Patent Foramen Ovale (PFO) device~* Platelets \< 100,000 or hemoglobin \< 10~* Left ventricular ejection fraction (LVEF) \< 30%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WATCHMAN (Type: EXPERIMENTAL): Implant of WATCHMAN Left Atrial Appendage Closure Technology
- Warfarin control (Type: ACTIVE_COMPARATOR): Subjects are treated with current standard of care Oral Anticoagulation Therapy with Warfarin
- Roll-in (Type: OTHER): Implant of WATCHMAN Left Atrial Appendage Closure Technology. Up to 3 non-randomized subjects per site, these subjects were not included in the primary analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Normal menstrual history with regular cycles and with a minimum of 21 days between menses~* Sexually abstinent or in a stable, mutually monogamous relationship with a partner who is HIV uninfected~* Agree to abstain from sexual intercourse and to not use vaginal products within 48 hours of study entry and for the duration of the study~Exclusion Criteria:~* HIV infected~* Sexually transmitted infection within 6 months of study entry~* Use of nontherapeutic intravenous drugs within 12 months of study entry~* Menopausal~* Currently using hormonal contraception or have used hormonal contraception within 2 months of study entry~* Menstruating at screening or enrollment visits~* Positive urine culture~* Positive chlamydia, gonorrhea, or trichomonas result at screening~* Abnormal Pap smear~* Clinically detectable genital abnormality. More information on this criterion can be found in the protocol.~* History of toxic shock syndrome or a history of symptoms suggesting toxic shock syndrome~* History of intermenstrual bleeding within 3 months of study entry~* Previous gynecologic surgery or have received treatment for syphilis, genital herpes, chlamydia, gonorrhea, trichomonas, or genital warts within 6 months of study entry~* Received treatment for Candida, bacterial vaginosis, or urinary tract infection within 1 month of study entry~* Have douched or used vaginal products, including lubricants, feminine hygiene products, vaginal drying agents, and sex toys within 48 hours of study entry~* Acute or chronic hepatitis B virus infection~* Liver or kidney abnormalities~* Oral antibiotics within 7 days of study entry~* Pregnant, less than 6 months postpartum, or breastfeeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Application of 1% tenofovir gel for 14 consecutive days between menses
- 2 (Type: PLACEBO_COMPARATOR): Application of 1% tenofovir placebo gel for 14 consecutive days between menses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women between the ages of 20 and 45~* Have used effective contraception for 2 weeks prior to starting in the study~* Does not have a temperature within 24 hours before the first injection~Exclusion Criteria:~* Prior history of genital warts~* More than 4 lifetime sexual partners~* Have undergone hysterectomy~* Have active cervical disease or history of cervical disease

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- qHPV (Type: EXPERIMENTAL): Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete